State Street
SLS icon

State Street’s SELLAS Life Sciences SLS Stock Holding History

State Street’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$192M Buy
12,996,558
+4,600,202
+55% +$31.8M 0.01% 1071
2026
Q1 		$35.5M Buy
8,396,356
+6,208,185
+284% +$27.8M ﹤0.01% 1930
2025
Q4 		$8.25M Buy
2,188,171
+827,257
+61% +$1.61M ﹤0.01% 2741
2025
Q3 		$2.19M Buy
1,360,914
+248,209
+22% +$442K ﹤0.01% 3311
2025
Q2 		$2.44M Buy
1,112,705
+835,676
+302% +$1.28M ﹤0.01% 3241
2025
Q1 		$299K Buy
277,029
+49,300
+22% +$58.5K ﹤0.01% 3733
2024
Q4 		$237K Buy
227,729
+53,200
+30% +$60.7K ﹤0.01% 3807
2024
Q3 		$218K Buy
174,529
+40,500
+30% +$49.5K ﹤0.01% 3807
2024
Q2 		$159K Buy
134,029
+36,900
+38% +$50.2K ﹤0.01% 3881
2024
Q1 		$98.1K Hold
97,129
– – ﹤0.01% 4033
2023
Q4 		$103K Hold
97,129
– – ﹤0.01% 4052
2023
Q3 		$159K Hold
97,129
– – ﹤0.01% 3993
2023
Q2 		$152K Hold
97,129
– – ﹤0.01% 4091
2023
Q1 		$139K Buy
97,129
+25,400
+35% +$62.8K ﹤0.01% 4200
2022
Q4 		$169K Buy
71,729
+13,523
+23% +$37.9K ﹤0.01% 4171
2022
Q3 		$118K Buy
58,206
+6,970
+14% +$19.2K ﹤0.01% 4398
2022
Q2 		$114K Hold
51,236
– – ﹤0.01% 4469
2022
Q1 		$342K Buy
51,236
+13,768
+37% +$80.5K ﹤0.01% 4192
2021
Q4 		$207K Hold
37,468
– – ﹤0.01% 4334
2021
Q3 		$343K Hold
37,468
– – ﹤0.01% 4126
2021
Q2 		$416K Buy
+37,468
New +$366K ﹤0.01% 3928
2018
Q1 		– Sell
-76
Closed -$30K – 3781
2017
Q4 		$30K Hold
76
– – ﹤0.01% 3667
2017
Q3 		$40K Hold
76
– – ﹤0.01% 3678
2017
Q2 		$66K Sell
76
-97
-56% -$84.4K ﹤0.01% 3573
2017
Q1 		$153K Buy
173
+78
+82% +$129K ﹤0.01% 3522
2016
Q4 		$274K Buy
+95
New +$552K ﹤0.01% 3465

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street's SLS Position: Q2 2026 in Review

State Street increased its SELLAS Life Sciences (SLS) stake by 55% in Q2 2026, buying an estimated $31.8M and bringing the position to 12,996,558 shares worth $192M. The position accounts for 0.01% of the portfolio, ranked #1071.

State Street first reported a position in SLS in Q4 2016 and has held it in 26 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • State Street held 12,996,558 shares of SELLAS Life Sciences worth $192M as of Q2 2026.
  • State Street bought 4,600,202 SELLAS Life Sciences shares in Q2 2026, an estimated $31.8M.
  • SELLAS Life Sciences made up 0.01% of State Street's portfolio in Q2 2026, its #1071 holding.
  • State Street first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 26 quarters since.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.